Revolutionary COPD treatment: FDA approves Verona Pharma’s Ohtuvayre – sales to hit $1.1BN by 2029

The US Food and Drug Administration (FDA) has approved Verona Pharmaâs Ohtuvayre (ensifentrine), marking a significant milestone in the treatment of chronic obstructive pulmonary disease (COPD).